Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $574,536.66 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 38,074 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $15.09, for a total transaction of $574,536.66. Following the sale, the insider directly owned 321,967 shares of the company’s stock, valued at $4,858,482.03. The trade was a 10.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Francis Lo also recently made the following trade(s):

• On Monday, January 12th, Francis Lo sold 79,590 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $17.73, for a total transaction of $1,411,130.70.
• On Friday, January 2nd, Francis Lo sold 3,125 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $16.08, for a total transaction of $50,250.00.
• On Monday, December 22nd, Francis Lo sold 4,394 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.50, for a total transaction of $76,895.00.
• On Monday, December 15th, Francis Lo sold 113,890 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.57, for a total transaction of $1,773,267.30.

Adaptive Biotechnologies Stock Up 0.6%

ADPT traded up $0.09 during trading on Monday, hitting $14.95. The company’s stock had a trading volume of 3,493,266 shares, compared to its average volume of 1,536,238. The business’s 50 day simple moving average is $16.76 and its 200-day simple moving average is $15.87. The firm has a market cap of $2.30 billion, a PE ratio of -37.37 and a beta of 2.19. Adaptive Biotechnologies Corporation has a one year low of $6.26 and a one year high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. The firm had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company’s revenue for the quarter was up 51.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.23) EPS. Equities research analysts expect that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies in the fourth quarter worth about $28,000. Sound Income Strategies LLC bought a new stake in Adaptive Biotechnologies in the 3rd quarter worth approximately $30,000. EverSource Wealth Advisors LLC raised its holdings in shares of Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after acquiring an additional 1,565 shares in the last quarter. Assetmark Inc. boosted its position in shares of Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after acquiring an additional 2,708 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies in the fourth quarter valued at $51,000. Institutional investors own 99.17% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ADPT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. JPMorgan Chase & Co. upped their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Guggenheim increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. BTIG Research upped their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Finally, Wall Street Zen lowered Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $18.25.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.